Johnson & Johnson SG&A Expenses 2012-2026 | JNJ
Johnson & Johnson annual/quarterly sg&a expenses history and growth rate from 2012 to 2026. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Johnson & Johnson sg&a expenses for the quarter ending March 31, 2026 were $6.034B, a 18.04% increase year-over-year.
- Johnson & Johnson sg&a expenses for the twelve months ending March 31, 2026 were $24.598B, a 8.25% increase year-over-year.
- Johnson & Johnson annual sg&a expenses for 2025 were $23.676B, a 3.53% increase from 2024.
- Johnson & Johnson annual sg&a expenses for 2024 were $22.869B, a 6.31% increase from 2023.
- Johnson & Johnson annual sg&a expenses for 2023 were $21.512B, a 6.25% increase from 2022.
|
Johnson & Johnson Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025 | $23,676 |
| 2024 | $22,869 |
| 2023 | $21,512 |
| 2022 | $20,246 |
| 2021 | $20,118 |
| 2020 | $22,084 |
| 2019 | $22,178 |
| 2018 | $22,540 |
| 2017 | $21,520 |
| 2016 | $20,067 |
| 2015 | $21,203 |
| 2014 | $21,954 |
| 2013 | $21,830 |
| 2012 | $20,869 |
| 2011 | $20,969 |
|
Johnson & Johnson Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $6,034 |
| 2025-12-31 | $6,753 |
| 2025-09-30 | $5,922 |
| 2025-06-30 | $5,889 |
| 2025-03-31 | $5,112 |
| 2024-12-31 | $6,453 |
| 2024-09-30 | $5,478 |
| 2024-06-30 | $5,681 |
| 2024-03-31 | $5,257 |
| 2023-12-31 | $5,810 |
| 2023-09-30 | $5,400 |
| 2023-06-30 | $5,396 |
| 2023-03-31 | $4,906 |
| 2022-12-31 | $3,107 |
| 2022-09-30 | $4,975 |
| 2022-06-30 | $6,226 |
| 2022-03-31 | $5,938 |
| 2021-12-31 | $2,613 |
| 2021-09-30 | $6,000 |
| 2021-06-30 | $6,073 |
| 2021-03-31 | $5,432 |
| 2020-12-31 | $6,457 |
| 2020-09-30 | $5,431 |
| 2020-06-30 | $4,993 |
| 2020-03-31 | $5,203 |
| 2019-12-31 | $6,039 |
| 2019-09-30 | $5,374 |
| 2019-06-30 | $5,546 |
| 2019-03-31 | $5,219 |
| 2018-12-31 | $5,991 |
| 2018-09-30 | $5,543 |
| 2018-06-30 | $5,743 |
| 2018-03-31 | $5,263 |
| 2017-12-31 | $6,045 |
| 2017-09-30 | $5,423 |
| 2017-06-30 | $5,289 |
| 2017-03-31 | $4,763 |
| 2016-12-31 | $5,431 |
| 2016-09-30 | $4,772 |
| 2016-06-30 | $5,176 |
| 2016-03-31 | $4,688 |
| 2015-12-31 | $5,891 |
| 2015-09-30 | $5,081 |
| 2015-06-30 | $5,384 |
| 2015-03-31 | $4,847 |
| 2014-12-31 | $5,822 |
| 2014-09-30 | $5,468 |
| 2014-06-30 | $5,481 |
| 2014-03-31 | $5,183 |
| 2013-12-31 | $5,917 |
| 2013-09-30 | $5,314 |
| 2013-06-30 | $5,376 |
| 2013-03-31 | $5,223 |
| 2012-12-31 | $5,661 |
| 2012-09-30 | $5,228 |
| 2012-06-30 | $4,965 |
| 2012-03-31 | $5,015 |
| 2011-12-31 | $5,458 |
| 2011-09-30 | $5,240 |
| 2011-06-30 | $5,215 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |